Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
138 stopped studies mapped to Malignant Bile Duct Neoplasm and descendants · 91% state a reason
Over the 138 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With…(RELEASE) | Phase 2 | terminated | Sep 23, 2019 | PCI Biotech AS | Recent results from a Phase 3 study are expected to change the standard of care for patients with… | Other (stated, no rule matched) |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy… | Phase 2 | terminated | Sep 28, 2020 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The… | Phase 1 | withdrawn | Aug 22, 2022 | M.D. Anderson Cancer Center | Per PI's request | Other (stated, no rule matched) |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic… | Phase 3 | terminated | Apr 15, 2008 | NCIC Clinical Trials Group | due to poor accrual | Enrollment / accrual |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | terminated | May 30, 2014 | QED Therapeutics, a BridgeBio company | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints).… | Safety / toxicity |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | — | terminated | Mar 10, 2006 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | Phase 2 | terminated | Sep 3, 2019 | Sunnybrook Health Sciences Centre | Lack of Funding | Funding |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | Phase 1 | terminated | Mar 11, 2020 | Danielle Kim Turgeon | Terminated due to lack of dimer. | Other (stated, no rule matched) |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar…(ENBD) | N/A | withdrawn | Nov 27, 2017 | Changhai Hospital | Failure to recruit patients | Enrollment / accrual |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic… | Phase 1 | terminated | Feb 2, 2012 | Washington University School of Medicine | Equipment that was used in the study was discontinued | Other (stated, no rule matched) |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating…(HOPE) | N/A | withdrawn | Jan 22, 2021 | Poitiers University Hospital | No enrollment | Enrollment / accrual |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase 2 | withdrawn | May 20, 2021 | Walid Shaib, MD | Funder decision | Other (stated, no rule matched) |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy… | Phase 2 | withdrawn | Sep 14, 2020 | Samsung Medical Center | problem of sponsor | Other (stated, no rule matched) |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | Phase 2 | terminated | Jan 27, 2021 | AIO-Studien-gGmbH | Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine… | Enrollment / accrual |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | Phase 1 | withdrawn | Jul 21, 2020 | Jordan Kharofa | Difficulty accruing | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment… | Phase 2 | withdrawn | Aug 25, 2021 | Fudan University | Repeat registration | Other (stated, no rule matched) |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Phase 2 | terminated | Dec 1, 2020 | American University of Beirut Medical Center | pharma company decision to withdraw the financial and IMP support | Funding |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab… | Phase 2 | terminated | Dec 5, 2016 | Aiwu Ruth He, MD | Manufacturer discontinued Sylatron | Drug supply |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | N/A | withdrawn | Aug 13, 2020 | Michael Lidsky, M.D. | No subjects enrolled due to availability of device commercially. | Enrollment / accrual |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic… | Phase 2 | withdrawn | Jul 21, 2020 | Jiangsu HengRui Medicine Co., Ltd. | It is difficult to screening subject | Other (stated, no rule matched) |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | Phase 2 | withdrawn | May 22, 2020 | Sun Yat-sen University | no patient enrolled | Enrollment / accrual |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | withdrawn | Jan 11, 2019 | Sun Yat-sen University | Protocol modification | Other (stated, no rule matched) |
| NCT03172832 | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors(INTERCPT) | N/A | terminated | Jun 1, 2017 | Medical University of South Carolina | Slow accrual; recommended by DSMB. | Enrollment / accrual |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT03211169 | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps… | N/A | terminated | Jul 7, 2017 | Stanford University | Inadequate enrollment | Enrollment / accrual |
| NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar… | Phase 3 | terminated | Mar 10, 2014 | Concordia Laboratories Inc. | Accrual rate remaining too low | Enrollment / accrual |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer… | Phase 2 | terminated | May 24, 2007 | National Cancer Institute (NCI) | Due to slow accrual | Enrollment / accrual |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar… | Phase 2 | terminated | Nov 4, 2016 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Business Decision | Sponsor / business decision |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | Phase 2 | suspended | Dec 19, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in… | Phase 2 | terminated | May 16, 2013 | Hellenic Cooperative Oncology Group | not stated | Not stated |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | Phase 2 | terminated | Oct 2, 2014 | Allina Health System | lack of funding | Funding |
| NCT02204124 | Whipple Procedure: Standard of Care vs. Thunderbeat | N/A | terminated | Jul 30, 2014 | Washington University School of Medicine | Principal Investigator and Study Sponsor decided to terminate the study early | Investigator |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | Phase 2 | terminated | Jan 30, 2009 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or… | Phase 2 | terminated | Feb 27, 2015 | National Health Research Institutes, Taiwan | ROS1 in IHC and gene rearrangement result can not match。No tumor response。 | Other (stated, no rule matched) |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish… | — | withdrawn | Jan 8, 2008 | Memorial Sloan Kettering Cancer Center | Data from MSK-IMPACT is sufficient for relevant analyses going forward | Other (stated, no rule matched) |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant… | Phase 3 | withdrawn | Mar 15, 2017 | University of Louisville | Competing study | Other (stated, no rule matched) |
| NCT01721174 | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | N/A | terminated | Nov 5, 2012 | Chinese University of Hong Kong | Poor recruitment | Enrollment / accrual |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With… | Phase 1 / Phase 2 | terminated | Aug 10, 2009 | University of Miami | Lack of Funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 11, 2023source: clinicaltrials